Acne-associated syndromes: Models for better understanding of acne pathogenesis

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 6, 2011, Pages 637-646

  Chen, W ^a   Obermayer Pietsch, B ^b   Hong, J B ^c   Melnik, B C ^d   Yamasaki, O ^e   Dessinioti, C ^f   Ju, Q ^g   Liakou, A I ^h   Al Khuzaei, S ^a   Katsambas, A ^f   Ring, J ^a,i   Zouboulis, C C ^h  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF OSNABRÜCK   (Germany)

^e OKAYAMA UNIVERSITY   (Japan)

^f UNIVERSITY OF ATHENS   (Greece)

^g Shanghai Skin Disease and STD Hospital   (China)

^h DESSAU MEDICAL CENTER   (Germany)

ⁱ HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

acne; Apert syndrome; insulin resistance; PAPA syndrome; PCO syndrome; SAPHO syndrome

Indexed keywords

ANDROGEN; ANTIANDROGEN; CALCITONIN; CONTRACEPTIVE AGENT; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DAPSONE; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUDROCORTISONE; GLUCOCORTICOID; HYDROXYPROGESTERONE; INFLIXIMAB; INSULIN SENSITIZING AGENT; ISOTRETINOIN; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETINOIC ACID; SALAZOSULFAPYRIDINE;

ACNE; ACROCEPHALOSYNDACTYLY; ALTERNATIVE MEDICINE; AUTOINFLAMMATORY DISEASE; BEDTIME DOSAGE; CONGENITAL ADRENAL HYPERPLASIA; DISEASE ASSOCIATION; HUMAN; HYPERANDROGENISM; HYPERANDROGENISM INSULIN RESISTANCE ACANTHOSIS NIGRICAN SYNDROME; HYPOALDOSTERONISM; INSULIN RESISTANCE; LOW DRUG DOSE; OVARY POLYCYSTIC DISEASE; PAPA SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PUSTULOSIS; REVIEW; SAPHO SYNDROME; SEBORRHEA; SEBORRHOEA ACNE HIRSUTISM ANDROGENETIC ALOPECIA SYNDROME; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ACANTHOSIS NIGRICANS; ACNE VULGARIS; ACQUIRED HYPEROSTOSIS SYNDROME; ACROCEPHALOSYNDACTYLIA; ADRENAL HYPERPLASIA, CONGENITAL; ALOPECIA; ARTHRITIS, INFECTIOUS; DERMATITIS, SEBORRHEIC; FEMALE; HIRSUTISM; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; PYODERMA GANGRENOSUM; SYNDROME;

EID: 79955888017     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03937.x     Document Type: Review

References (120)

1. Zouboulis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne? Exp Dermatol 2005; 14: 143-152. (Pubitemid 40277582)
2. Xia LQ, Zouboulis C, Detmar M, et al. Isolation of human sebaceous glands and cultivation of sebaceous gland-derived cells as an in vitro model. J Invest Dermatol 1989; 93: 315-321. (Pubitemid 19216063)
3. Guy R, Ridden C, Kealey T,. The improved organ maintenance of the human sebaceous gland: modeling in vitro the effects of epidermal growth factor, androgens, estrogens, 13-cis retinoic acid, and phenol red. J Invest Dermatol 1996; 106: 454-460. (Pubitemid 26117583)
4. Zouboulis CC, Seltmann H, Neitzel H, Orfanos CE,. Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). J Invest Dermatol 1999; 113: 1011-1020. (Pubitemid 30013346)
5. Zouboulis CC, Schagen S, Alestas T,. The sebocyte culture-a model to study the pathophysiology of the sebaceous gland in sebostasis, seborrhoea and acne. Arch Dermatol Res 2008; 300: 397-413.
6. Frost P, Gomez EC,. Inhibitors of sex hormones: development of experimental models. Adv Biol Skin 1972; 12: 403-420.
7. Guy R, Ridden C, Barth J, Kealey T,. Isolation and maintenance of the human pilosebaceous duct: 13-cis retinoic acid acts directly on the duct in vitro. Br J Dermatol 1993; 128: 242-248. (Pubitemid 23075930)
8. Mirshahpanah P, Maibach HI,. Models in acnegenesis. Cutan Ocul Toxicol 2007; 26: 195-202. (Pubitemid 47237794)
9. Zouboulis CC,. Propionibacterium acnes and sebaceous lipogenesis: a love-hate relationship? J Invest Dermatol 2009; 129: 2093-2096.
10. Nakatsuji T, Liu Y-T, Huang C-P, et al. Antibodies elicited by inactivated Propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris. J Invest Dermatol 2008; 128: 2451-2457.
11. Dessinioti C, Katsambas AD,. Congenital adrenal hyperplasia. Dermatoendocrinol 2009; 1: 87-91.
12. Trakakis E, Basios G, Trompoukis P, et al. An update on 21-hydroxylase deficient congenital adrenal hyperplasia. Gynecol Endocrinol 2010; 26: 63-71.
13. New MI,. An update of congenital adrenal hyperplasia. Ann N Y Acad Sci 2004; 1038: 14-43. (Pubitemid 40577441)
14. Speiser PW, White PC,. Congenital adrenal hyperplasia. N Engl J Med 2003; 349: 776-788. (Pubitemid 37010783)
15. New MI,. Extensive clinical experience. Nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4205-4214. (Pubitemid 44833386)
16. Gonzalez ME, Cantatore-Francis J, Orlow SJ,. Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. Br J Dermatol 2010; 163: 378-385.
17. Karrer-Voegeli S, Rey F, Reymond MJ, et al. Androgen dependence of hirsutism, acne and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore) 2009; 88: 32-45.
18. Caputo V, Fiorella S, Curiale S, et al. Refractory acne and 21-hydroxylase deficiency in a selected group of female patients. Dermatology 2010; 220: 121-127.
19. Lucky A, Rosenfield R, McGuine J, et al. Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 1986; 62: 840-848. (Pubitemid 16106706)
20. Rosenfield RL,. What every physician should know about polycystic ovary syndrome. Dermatol Ther 2008; 21: 354-361.
21. Trakakis E, Rizos D, Loghis C, et al. The prevalence of non-classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Greek women with hirsutism and polycystic ovary syndrome. Endocr J 2008; 55: 33-39. (Pubitemid 351520177)
22. Escobar-Morreale HF, Snachon R, San Millan JL,. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008; 93: 5275-5283.
23. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89: 453-462. (Pubitemid 38269843)
24. Saygili F, Oge A, Yilmaz C,. Hyperinsulinemia and insulin insensitivity in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the relationship between leptin levels and chronic hyperinsulinemia. Horm Res 2005; 63: 270-274. (Pubitemid 41159839)
25. Dessinioti C, Katsambas A, Congenital adrenal hyperplasia and acne in male patients. In:, Zouboulis CC, Katsambas AD, Kligman AM, eds. Acne Vulgaris and Rosacea: Pathogenesis and Treatment. Springer, Heidelberg, in press.
26. Degitz K, Placzek M, Arnold B, et al. Congenital adrenal hyperplasia and acne in male patiens. Br J Dermatol 2003; 148: 1263-1266. (Pubitemid 36819231)
27. Orfanos CE,. Antiandrõgenos en dermatología. Arch Arg Derm 1982; 32 (Suppl. 1): 51-55.
28. Orfanos CE, Adler YA, Zouboulis CC,. The SAHA syndrome. Horm Res 2000; 54: 251-258. (Pubitemid 34701730)
29. Zouboulis CC, Chen W, Thornton MJ, et al. Sexual hormones in human skin. Horm Metab Res 2007; 39: 85-95. (Pubitemid 46540281)
30. Lowenstein EJ,. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther 2006; 19: 210-223. (Pubitemid 44386588)
31. Carmina E,. Mild androgen phenotypes. Best Pract Res Clin Endocrinol Metab 2006; 20: 207-220. (Pubitemid 44182756)
32. Karrer-Voegeli S, Rey F, Reymond MJ, et al. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine 2009; 88: 3-45.
33. Essah PA, Wickham EP 3rd, Nunley JR, Nestler JE,. Dermatology of androgen-related disorders. Clin Dermatol 2006; 24: 289-298. (Pubitemid 43977876)
34. Zouboulis CC,. Acne and sebaceous gland function. Clin Dermatol 2004; 22: 360-366. (Pubitemid 39535276)
35. Chen W, Zouboulis CC,. Hormones and the pilosebaceous unit. Dermatoendocrinol 2009; 1: 81-86.
36. Youn SW,. The role of facial sebum secretion in acne pathogenesis: facts and controversies. Clin Dermatol 2010; 28: 8-11.
37. Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009; 18: 821-832.
38. Zouboulis CC,. Acne vulgaris-Rolle der Hormone. Hautarzt 2010; 61: 107-114.
39. Somani N, Harrison S, Bergfeld WF,. The clinical evaluation of hirsutism. Dermatol Ther 2008; 21: 376-391.
40. Carmina E, Rosato F, Jannà A, et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91: 2-6. (Pubitemid 43069106)
41. Bachelot A, Chabbert-Buffet N, Salenave S, et al. Anti-androgen treatments. Ann Endocrinol (Paris) 2010; 71: 19-24.
42. Zouboulis CC, Rabe T,. Hormonelle Antiandrogene in der Aknetherapie. J Dtsch Dermatol Ges 2010; 8 (Suppl. 1): S60-S74.
43. Ehrmann DA,. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236.
44. Wehr E, Pilz S, Schweighofer N, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol 2009; 161: 575-582.
45. Recabarren SE, Smith R, Rios R, et al. Metabolic profile in sons of women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2008; 93: 3318-3324.
46. Ewens KG, Stewart DR, Ankener W, et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: 2306-2315.
47. Deligeoroglou E, Kouskouti C, Christopoulos P,. The role of genes in the polycystic ovary syndrome: predisposition and mechanisms. Gynecol Endocrinol 2009; 25: 603-609.
48. Wehr E, Schweighofer N, Möller R, et al. Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome. Metabolism 2010; 59: 575-580.
49. Rosenfield RL,. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28: 265-293. (Pubitemid 29242714)
50. Kelekci KH, Kelekci S, Incki K, et al. Ovarian morphology and prevalence of polycystic ovary syndrome in reproductive aged women with or without mild acne. Int J Dermatol 2010; 49: 775-779.
51. Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 5801-5807. (Pubitemid 38033054)
52. Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome-a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92: 4546-4556. (Pubitemid 350223423)
53. Seow KM, Juan CC, Hwang JL, Ho L,. Laparoscopic surgery in polycystic ovary syndrome: reproductive and metabolic effects. Semin Reprod Med 2008; 26: 101-110.
54. Glueck CJ, Goldenberg N, Sieve L, Wang P,. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. Metabolism 2008; 57: 954-960. (Pubitemid 351814688)
55. Pasquali R, Gambineri A,. Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol 2006; 154: 763-775. (Pubitemid 43997712)
56. Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75: 46-52. (Pubitemid 32041226)
57. Rager KM, Omar HA,. Androgen excess disorders in women: the severe insulin-resistant hyperandrogenic syndrome, HAIR-AN. Sci World J 2006; 6: 116-121.
58. Omar HA, Logsdon S, Richards J,. Clinical profiles, occurrence, and management of adolescent patients with HAIR-AN syndrome. Sci World J 2004; 4: 507-511.
59. Elmer KB, George RM,. HAIR-AN syndrome: a multisystem challenge. Am Fam Physician 2001; 63: 2385-2390. (Pubitemid 32601412)
60. Shen Z, Hao F, Wei P,. HAIR-AN syndrome in a male adolescent with concomitant vitiligo. Arch Dermatol 2009; 145: 492-494.
61. Ingletto D, Ruggiero L, De Sanctis V,. HAIR-AN syndrome (hyperandrogenism, insulin resistance, acanthosis nigricans) in an adolescent with Cohen's syndrome. Minerva Pediatr 2001; 53: 493-494.
62. Musso C, Cochran E, Moran SA, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) 2004; 83: 209-222. (Pubitemid 38955444)
63. Blomberg M, Jeppesen EM, Skovby F, Benfeldt E,. FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature. Dermatology 2010; 220: 297-305.
64. Makrantonaki E, Vogel K, Fimmel S, et al. Interplay of IGF-I and 17beta-estradiol at age-specific levels in human sebocytes and fibroblasts in vitro. Exp Gerontol 2008; 43: 939-946.
65. Lara-Castro C, Garvey WT,. Intracellular lipid accumulation in liver and muscle and the insulin resistance syndrome. Endocrinol Metab Clin North Am 2008; 37: 841-856.
66. Smith TM, Gilliland K, Clawson GA, Thiboutot D,. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 2008; 128: 1286-1293. (Pubitemid 351543201)
67. Zemtsov A, Wilson L,. Successful treatment of hirsutism in HAIR-AN syndrome using flutamide, spironolactone, and birth control therapy. Arch Dermatol 1997; 133: 431-433. (Pubitemid 27175689)
68. Manco M, Castagneto M, Nanni G, et al. Biliopancreatic diversion as a novel approach to the HAIR-AN syndrome. Obes Surg 2005; 15: 286-289. (Pubitemid 40316019)
69. Pfeifer SL, Wilson RM, Gawkrodger DJ,. Clearance of acanthosis nigricans associated with the HAIR-AN syndrome after partial pancreatectomy: an 11-year follow-up. Postgrad Med J 1999; 75: 421-422. (Pubitemid 29329198)
70. Chamot AM, Vion B, Gerster JC,. Acute pseudoseptic arthritis and palmoplantar pustulosis. Clin Rheumatol 1986; 5: 118-123. (Pubitemid 16167873)
71. Kahn MF, Khan MA,. The SAPHO syndrome. Baillieres Clin Rheumatol 1994; 8: 333-362. (Pubitemid 24189843)
72. Govoni M, Colina M, Massara A, Trotta F,. SAPHO syndrome and infections. Autoimmun Rev 2009; 8: 256-259.
73. Gmyrek R, Grossman ME, Rudin D, Scher R,. SAPHO syndrome: report of three cases and review of the literature. Cutis 1999; 64: 253-258.
74. Yamasaki O, Iwatsuki K, Kaneko F,. A case of SAPHO syndrome with pyoderma gangrenosum and inflammatory bowel disease masquerading as BehÃet's disease. Adv Exp Med Bio 2003; 528: 339-341.
75. Kahn MF, Bouvier M, Palazzo E, et al. Sternoclavicular pustulotic osteitis (SAPHO). 20-year interval between skin and bone lesions. J Rheumatol 1991; 18: 1104-1108.
76. Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Arthritis Rheum 1999; 29: 159-171. (Pubitemid 30013280)
77. Laredo JD, Vuillemin-Bodaghi V, Boutry N, et al. SAPHO syndrome: MR appearance of vertebral involvement. Radiology 2007; 242: 825-831.
78. Hamada T, Matsuura H, Oono T, et al. Karyotypic analysis of bone marrow cells in pyodermic lesions associated with myelodysplastic syndrome. Arch Dermatol 2008; 144: 643-648. (Pubitemid 351724425)
79. Colina M, Lo Monaco A, Khodeir M, Trotta F,. Propionibacterium acnes and SAPHO syndrome: a case report and literature review. Clin Exp Rheumatol 2007; 25: 457-460. (Pubitemid 47091025)
80. Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, et al. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology 2008; 47: 1160-1167. (Pubitemid 352038220)
81. Olivieri I, Padula A, Palazzi C,. Pharmacological management of SAPHO syndrome. Expert Opin Investig Drugs 2006; 15: 1229-1233. (Pubitemid 44608261)
82. Iqbal M, Kolodney MS,. Acne fulminans with synovitis-acne-pustulosis- hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol 2005; 52 (Suppl): S118-120.
83. Amital H, Applbaum YH, Aamar S, et al. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology 2004; 43: 658-661. (Pubitemid 38628200)
84. Galadari H, Bishop AG, Venna SS, et al. Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated with a combination of isotretinoin and pamidronate. J Am Acad Dermatol 2009; 61: 123-125.
85. Lindor NM, Arsenault TM, Solomon H, et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: Papa syndrome. Mayo Clin Proc 1997; 72: 611-615. (Pubitemid 27330245)
86. Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002; 11: 961-969. (Pubitemid 34449783)
87. Kanazawa N, Furukawa F,. Autoinflammatory syndromes with a dermatological perspective. J Dermatol 2007; 34: 601-618. (Pubitemid 47313251)
88. Wise CA, Bennett LB, Pascual V, et al. Localization of a gene for familial recurrent arthritis. Arthritis Rheum 2000; 43: 2041-2045.
89. Cortis E, De Benedetti F, Insalaco A, et al. Abnormal production of tumor necrosis factor (TNF)-alpha and clinical efficacy of the tnf inhibitor etanercept in a patient with PAPA syndrome [corrected]. J Pediatr 2004; 145: 851-855. (Pubitemid 39586631)
90. Tallon B, Corkill M,. Peculiarities of PAPA syndrome. Rheumatology (Oxford) 2006; 45: 1140-1143. (Pubitemid 44542104)
91. Renn CN, Helmer A, Megahed M,. pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA syndrome). Hautarzt 2007; 58: 383-384. (Pubitemid 46739802)
92. Hong JB, Su YN, Chiu HC,. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the cd2bp1 gene. J Am Acad Dermatol 2009; 61: 533-535.
93. Shoham NG, Centola M, Mansfield E, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 2003; 100: 13501-13506. (Pubitemid 37444771)
94. McDermott MF, Aksentijevich I,. The autoinflammatory syndromes. Curr Opin Allergy Clin Immunol 2002; 2: 511-516. (Pubitemid 36105814)
95. Stichweh DS, Punaro M, Pascual V,. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with papa syndrome. Pediatr Dermatol 2005; 22: 262-265. (Pubitemid 40741268)
96. Edrees AF, Kaplan DL, Abdou NI,. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) associated with hypogammaglobulinemia and elevated serum tumor necrosis factor-alpha levels. J Clin Rheumatol 2002; 8: 273-275.
97. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ,. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 2005; 44: 406-408. (Pubitemid 40361307)
98. Apert E,. De l'a acrocéphalosyndactylie. Bull Soc Med Hop (Paris) 1906; 23: 1310-1330.
99. Boulet SL, Rasmussen SA, Honein MA,. A population-based study of craniosynostosis in metropolitan Atlanta, 1989-2003. Am J Med Genet A 2008; 146A: 984-991.
100. Freiman A, Tessler O, Barankin B,. Apert syndrome. Int J Dermatol 2006; 45: 1341-1343. (Pubitemid 44696103)
101. Solomon LM, Fretzin DF, Pruzansky S,. Pilosebaceous abnormalities in Apert's syndrome. Arch Dermatol 1970; 102: 381-385.
102. Solomon L, Cohen M, Pruzansky S,. Pilosebaceous abnormalities in Apert type acrocephalosyndactyly. Birth Defects 1971; 7: 193-195.
103. Steffen C,. The acneiform eruption of Apert's syndrome is not acne vulgaris. Am J Dermatopathol 1984; 6: 213-220. (Pubitemid 14146786)
104. Melnik BC,. Role of FGFR2-signaling in the pathogenesis of acne. Dermatoendocrinol 2009; 1: 141-156.
105. Wilkie AO, Slaney SF, Oldridge M, et al. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nat Genet 1995; 9: 165-172.
106. Ahmed Z, Schuller AC, Suhling K, et al. Extracellular point mutations in FGFR2 elicit unexpected changes in intracellular signalling. Biochem J 2008; 413: 37-49. (Pubitemid 351946860)
107. Melnik BC,. FoxO1- the key for the pathogenesis and therapy of acne? J Dtsch Dermatol Ges 2010; 8: 105-114.
108. Melnik BC,. Is nuclear deficiency of FoxO1 due to increased growth factor/PI3K/Akt-signalling in acne vulgaris reversed by isotretinoin treatment? Br J Dermatol 2010; 162: 1398-1400.
109. Downs AM, Codon CA, Tan R,. Isotretinoin therapy for antibiotic- refractory acne in Apert's syndrome. Clin Exp Dermatol 1999; 24: 461-463. (Pubitemid 30010189)
110. Melnik BC, Schmitz G,. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. Exp Dermatol 2009; 18: 833-841.
111. Munro CS, Wilkie AOM,. Epidermal mosaicism producing localized acne: somatic mutation in FGFR2. Lancet 1998; 352: 704-705. (Pubitemid 28398709)
112. Melnik BC, Schmitz G, Zouboulis CC,. Anti-acne agents attenuate FGFR2 signal transduction in acne. J Invest Dermatol 2009; 129: 1868-1877.
113. Li L, Yang D, Chen X, et al. Clinical and metabolic features of polycystic ovary syndrome. Int J Gynaecol Obstet 2007; 97: 129-134. (Pubitemid 46589453)
114. Bonaventure J, El Ghouzzi V,. Molecular and cellular bases of syndromic craniosynostoses. Expert Rev Mol Med 2003; 5: 1-17.
115. Szabõ K, Tax G, Teodorescu-Brinzeu D, et al. TNFalpha gene polymorphisms in the pathogenesis of acne vulgaris. Arch Dermatol Res 2010 [Epub ahead of print; doi:].
116. Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009; 161: 1199-1201.
117. Thielitz A, Reinhold D, Vetter R, et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) target major pathogenetic steps in acne initiation. J Invest Dermatol 2007; 127: 1042-1051. (Pubitemid 46625127)
118. Chua SL, Angus JE, Ravenscroft J, Perkins W,. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome and acne fulminans: are they part of the same disease spectrum? Clin Exp Dermatol 2009; 34: e241-243.
119. Assmann G, Wagner AD, Monika M, et al. Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome. Rheumatol Int 2010; 30: 1273-1276.
120. Queiro R, Moreno P, Sarasqueta C, et al. Synovitis-acne-pustulosis- hyperostosis-osteitis syndrome and psoriatic arthritis exhibit a different immunogenetic profile. Clin Exp Rheumatol 2008; 26: 125-128. (Pubitemid 351385266)